Cardiological Biopharmaceuticals in the Conception of Drug Targeting Delivery: Practical Results and Research Perspectives

Overview

Journal Acta Naturae

Specialty Biology

Date 2012 Nov 15

PMID 23150805

Citations 1

Authors

A V Maksimenko

Affiliations

Soon will be listed here.

Abstract

The results of the clinical use of thrombolytic and antithrombotic preparations developed on the basis of protein conjugates obtained within the framework of the conception of drug targeting delivery in the organism are considered. A decrease has been noted in the number of biomedical projects focused on these derivatives as a result of various factors: the significant depletion of financial and organizational funds, the saturation of the pharmaceutical market with preparations of this kind, and the appearance of original means for interventional procedures. Factors that actively facilitate the conspicuous potentiation of the efficacy of bioconjugates were revealed: the biomedical testing of protein domains and their selected combinations, the optimization of molecular sizes for the bioconjugates obtained, the density of target localization, the application of cell adhesion molecules as targets, and the application of connected enzyme activities. Enzyme antioxidants and the opportunity for further elaboration of the drug delivery conception via the elucidation and formation of therapeutic targets for effective drug reactions by means of pharmacological pre- and postconditioning of myocardium arouse significant interest.

Citing Articles

Widening and Elaboration of Consecutive Research into Therapeutic Antioxidant Enzyme Derivatives.

Maksimenko A Oxid Med Cell Longev. 2016; 2016:3075695.

PMID: 27148430 PMC: 4842371. DOI: 10.1155/2016/3075695.

References

Tanaka K, Ishihara T, Azuma A, Kudoh S, Ebina M, Nukiwa T . Therapeutic effect of lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2009; 298(3):L348-60. DOI: 10.1152/ajplung.00289.2009. View

Jung O, Marklund S, Geiger H, Pedrazzini T, Busse R, Brandes R . Extracellular superoxide dismutase is a major determinant of nitric oxide bioavailability: in vivo and ex vivo evidence from ecSOD-deficient mice. Circ Res. 2003; 93(7):622-9. DOI: 10.1161/01.RES.0000092140.81594.A8. View

Chu Y, Iida S, Lund D, Weiss R, DiBona G, Watanabe Y . Gene transfer of extracellular superoxide dismutase reduces arterial pressure in spontaneously hypertensive rats: role of heparin-binding domain. Circ Res. 2003; 92(4):461-8. DOI: 10.1161/01.RES.0000057755.02845.F9. View

Hochtl T, Farhan S, Wojta J, Huber K . New anticoagulant agents in acute coronary syndromes. Heart. 2010; 97(3):244-52. DOI: 10.1136/hrt.2009.184333. View

Ishihara T, Tanaka K, Tasaka Y, Namba T, Suzuki J, Ishihara T . Therapeutic effect of lecithinized superoxide dismutase against colitis. J Pharmacol Exp Ther. 2008; 328(1):152-64. DOI: 10.1124/jpet.108.144451. View

Stralin P, Karlsson K, Johansson B, Marklund S . The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. Arterioscler Thromb Vasc Biol. 1995; 15(11):2032-6. DOI: 10.1161/01.atv.15.11.2032. View

Huber K, De Caterina R, Kristensen S, Verheugt F, Montalescot G, Badimon Maestro L . Pre-hospital reperfusion therapy: a strategy to improve therapeutic outcome in patients with ST-elevation myocardial infarction. Eur Heart J. 2005; 26(19):2063-74. DOI: 10.1093/eurheartj/ehi413. View

Sarembock I . From systemic shotgun to site-specific nanoparticle-targeted delivery: a new paradigm for drug delivery. Arterioscler Thromb Vasc Biol. 2008; 28(11):1879-81. DOI: 10.1161/ATVBAHA.108.175190. View

Landmesser U, Merten R, Spiekermann S, Buttner K, Drexler H, Hornig B . Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation. 2000; 101(19):2264-70. DOI: 10.1161/01.cir.101.19.2264. View

10.

Panchenko E . [Thrombocyte IIb/IIIa receptor inhibitors--a new direction in antithrombotic therapy]. Ter Arkh. 1997; 69(9):66-71. View

11.

Maksimenko A . [Third generation of plasminogen activators. New directions in research]. Bioorg Khim. 1999; 25(8):563-71. View

12.

Ganguly K, Murciano J, Westrick R, Leferovich J, Cines D, Muzykantov V . The glycocalyx protects erythrocyte-bound tissue-type plasminogen activator from enzymatic inhibition. J Pharmacol Exp Ther. 2007; 321(1):158-64. DOI: 10.1124/jpet.106.114405. View

13.

Shuvaev V, Han J, Yu K, Huang S, Hawkins B, Madesh M . PECAM-targeted delivery of SOD inhibits endothelial inflammatory response. FASEB J. 2010; 25(1):348-57. PMC: 3005426. DOI: 10.1096/fj.10-169789. View

14.

Davies M . The pathophysiology of acute coronary syndromes. Heart. 2000; 83(3):361-6. PMC: 1729334. DOI: 10.1136/heart.83.3.361. View

15.

Maksimenko A . Experimental antioxidant biotherapy for protection of the vascular wall by modified forms of superoxide dismutase and catalase. Curr Pharm Des. 2005; 11(16):2007-16. DOI: 10.2174/1381612054065756. View

16.

Lin S, Shyue S, Liu P, Chen Y, Ku H, Chen J . Adenovirus-mediated overexpression of catalase attenuates oxLDL-induced apoptosis in human aortic endothelial cells via AP-1 and C-Jun N-terminal kinase/extracellular signal-regulated kinase mitogen-activated protein kinase pathways. J Mol Cell Cardiol. 2004; 36(1):129-39. DOI: 10.1016/j.yjmcc.2003.10.011. View

17.

Shuvaev V, Tliba S, Pick J, Arguiri E, Christofidou-Solomidou M, Albelda S . Modulation of endothelial targeting by size of antibody-antioxidant enzyme conjugates. J Control Release. 2010; 149(3):236-41. PMC: 3043111. DOI: 10.1016/j.jconrel.2010.10.026. View

18.

Hamm C, Bertrand M, Braunwald E . Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet. 2001; 358(9292):1533-8. DOI: 10.1016/S0140-6736(01)06585-0. View

19.

Bode C, Smalling R, Berg G, Burnett C, Lorch G, KALBFLEISCH J . Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction..... Circulation. 1996; 94(5):891-8. DOI: 10.1161/01.cir.94.5.891. View

20.

Carlsson L, Marklund S, Edlund T . The rat extracellular superoxide dismutase dimer is converted to a tetramer by the exchange of a single amino acid. Proc Natl Acad Sci U S A. 1996; 93(11):5219-22. PMC: 39225. DOI: 10.1073/pnas.93.11.5219. View